Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis
Public ClinicalTrials.gov record NCT01585766. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Randomized Study of MEDI-551 in Subjects With Relapsing Forms of Multiple Sclerosis
Study identification
- NCT ID
- NCT01585766
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- MedImmune LLC
- Industry
- Enrollment
- 56 participants
Conditions and interventions
Conditions
Interventions
- MEDI-551 30 MG-IV Drug
- MEDI-551 60 MG-SC Drug
- PLACEBO-IV-SC Drug
- MEDI-551 100 MG-IV Drug
- MEDI-551 300 MG-SC Drug
- MEDI-551 600 MG-IV Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 23, 2012
- Primary completion
- Jan 1, 2015
- Completion
- Jun 19, 2016
- Last update posted
- Oct 28, 2018
2012 – 2016
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Scottsdale | Arizona | — | — |
| Research Site | Long Beach | California | — | — |
| Research Site | Sacramento | California | — | — |
| Research Site | Denver | Colorado | — | — |
| Research Site | Tampa | Florida | — | — |
| Research Site | Marlton | New Jersey | — | — |
| Research Site | Winston-Salem | North Carolina | — | — |
| Research Site | Cordova | Tennessee | — | — |
| Research Site | Houston | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01585766, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 28, 2018 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01585766 live on ClinicalTrials.gov.